Daxor Corporation to Exhibit at the Society of Nuclear Medicine and Molecular Imaging Mid-Winter and American College Nuclear Medicine Annual Meeting
30 January 2024 - 12:00AM
Daxor Corporation (Nasdaq:
DXR), the global leader in blood volume measurement
technology, today announces it will be exhibiting at the Society of
Nuclear Medicine and Molecular Imaging (SNMMI) Mid-Winter and
American College Nuclear Medicine (ACNM) Annual Meeting at the
Hilton Orlando Lake Buena Vista in Orlando, FL, February 1-3, 2024.
"This conference presents an exciting
opportunity to raise awareness and educate SNMMI and ACNM members
about the significant impact of our blood volume diagnostic. It
underscores their crucial role in providing clinicians with precise
information to optimize fluid management treatment, leading to
significant reductions in mortality, hospital readmission, length
of stay, and costs," said Kathryn Kornafel, Daxor's VP of Marketing
and Commercial Development.
The Company will be exhibiting at Booth #32.
Register for the conference HERE.
About the Society of Nuclear Medicine
and Molecular Imaging
The Society of Nuclear Medicine and Molecular
Imaging (SNMMI) is an international scientific and medical
organization dedicated to advancing nuclear medicine and molecular
imaging, vital elements of precision medicine that allow diagnosis
and treatment to be tailored to individual patients in order to
achieve the best possible outcomes. SNMMI’s members set the
standard for molecular imaging and nuclear medicine practice by
creating guidelines, sharing information through journals and
meetings and leading advocacy on key issues that affect molecular
imaging and therapy research and practice. For more information,
visit www.snmmi.org.
About the American College of Nuclear
Medicine
ACNM is composed of physicians and other nuclear
medicine professionals dedicated to enhancing the practice of
nuclear medicine through study, education, and improvement of
clinical practice. Our goal is to assure a legislative, legal,
regulatory, and economic framework that encourages and makes
practicable the safe, appropriate use of nuclear medicine
procedures to improve the quality of health care service available
to patients. For more information, visit www.acnm.org.
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global
leader in blood volume measurement technology focused on blood
volume testing innovation. We developed and market the BVA-100™
(Blood Volume Analyzer), the only diagnostic blood test cleared by
the FDA to provide safe, accurate, objective quantification of
blood volume status and composition compared to patient-specific
norms. Over 65,000+ tests have been performed at leading hospital
centers across the U.S., enhancing hospital performance metrics in
a broad range of surgical and medical conditions, including
significantly reducing mortality and readmissions in heart failure
and critical care. Daxor has several ongoing trials in the areas of
heart failure treatment with support from the NIH and is under
contract developing analyzers to improve combat casualty care with
the U.S. Department of Defense. Daxor's mission is to advance
healthcare by enabling optimal fluid management with blood volume
analysis. Daxor’s vision is optimal blood volume for all. For more
information, please visit our website at Daxor.com. Sign up to
receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:Bret ShapiroSr. Managing Partner,
CORE IR516-222-2560brets@coreir.com
Daxor (NASDAQ:DXR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Daxor (NASDAQ:DXR)
Historical Stock Chart
From Sep 2023 to Sep 2024